health
health · EN
Back Bay Life Science Advisors brings you expert insights from our strategic advisors and investment bankers on biopharma, medtech, and medical device development, trends, and growth areas. On this podcast, you’ll hear from our experts in life science development, commercialization, and investment banking, scientific investigators, biotech and medtech executives, physicians, and strategists who excel at guiding global life sciences companies and their investors through complex decisions. Join us for insights generated from in-depth scientific, strategic, and financial analysis at the intersection of science and business.
Required Pod Score for this podcast. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.
Contact path
Verified email
Booking probability
29%
Guest openness
Selective
Sign up to generate a grounded pitch for Back Bay Life Science Report.
Signup to Generate a PitchBack Bay Life Science Advisors brings you expert insights from our strategic advisors and investment bankers on biopharma, medtech, and medical device development, trends, and growth areas.
Recent episodes include "Evolving Oncology: The Expanding Landscape of Targeted Therapies and Investment" (15 April 2026, 30 minutes), "Evolving Oncology: The Expanding Landscape of Targeted Therapies and Investment" (15 April 2026, 30 minutes), and "ADC Revolution in Ovarian Cancer: Current Developments and Future Outlook" (5 March 2026, 30 minutes).
Back Bay Life Science Report publishes roughly monthly, with episodes averaging 27 minutes across 35 episodes.
Booking probability for Back Bay Life Science Report is 29%, and the host is rated Selective on guests. Back Bay Life Science Report requires a Pod Score of 80 or higher. Back Bay Life Science Report's contact route on record: verified email.
The strongest fits for Back Bay Life Science Report are Pharmaceuticals and Medical Devices & Supplies. Back Bay Life Science Report has a health audience.
Back Bay Life Science Report is a health podcast with 35 episodes published.
Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.
Back Bay Life Science Report
Examining the dynamic progress in targeted oncology, the episode delves into the shift from single-mutation therapies to broad pathway targeting, highlighting advances in EGFR, KRAS, and the MAPK axis. Recorded prior to...
Examining the dynamic progress in targeted oncology, the episode delves into the shift from single-mutation therapies to broad pathway targeting, highlighting advances in EGFR, KRAS, and the MAPK axis. Recorded prior to...
As ovarian cancer research enters a pivotal new era, Back Bay Life Science Advisors' Dr. Pete Bak is joined by Director Mavra Nasir and Consultant Trent Gordon for a deep dive into one of oncology's most active and...
Episode #33
As the life sciences industry turns the page to 2026, Back Bay Life Science Advisors’ Dr. Pete Bak and Dr. Mavra Nasir take a detailed look back at FDA drug approvals in 2025 , a year marked by regulatory turbulence...
In this DNB//Back Bay Healthcare Capital Markets podcast episode, Jim Cirenza, Head of Fixed Income and Equities at DNB, Kristoffer Braaten, Director and Head of Equity Capital Markets at DNB, and Vasilios Kofitsas...
Episode #31
The topic of bispecific antibodies has been an area of interest in the pharma space for a long time now. The recent news of the notable late-stage data from Akeso and Summit’s PD-1/VEGF bispecific antibody ivonescimab...
Episode #30
In this DNB//Back Bay Healthcare Capital Markets Episode, Vasilios Kofitsas, Partner and Managing Director at Back Bay Life Science Advisors speaks with Jim Cirenza and Kristoffer Braaten of DNB Bank in New York. They...
After a summer away from podcasting, Back Bay Life Science Advisors’ Dr. Pete Bak and Christian Thienel are back on the mic to discuss current market dynamics in liver disease with a focus on one of the most closely...
Episode #28
In this DNB//Back Bay Healthcare Capital Markets podcast episode, learn about the key considerations, mechanics and timelines of going public on a US exchange. Topics in this podcast include: An overview of the...
Episode #27
Guests: Pete Bak and Christian Thienel Length: 27 minutes In this episode of The Life Science Report, Dr. Pete Bak and Back Bay Director, Christian Thienel catch up on the area attracting the most industry interest over...
Episode #26
Welcome to another episode with the DNB//Back Bay Partnership for Healthcare. In this episode Jonathan Gertler, Back Bay CEO and Managing Partner, is once again joined by James Cirenza, Head of Fixed Income and Equities...
Guests: Pete Bak and Christian Thienel Length: 37 minutes With the advent of COVID-19 in 2020 and 2021, we saw a tremendous amount of interest in not only COVID vaccines, but other companies riding the tailwind and...
A Podcast Discussion on the Trends and Investment Activity in Radiopharmaceuticals and Psychedelics Guests: Pete Bak and Christian Thienel Length: 25 minutes Here at Back Bay we’ve seen a number of notable trends in the...
As we move into 2024, Back Bay’s strategic advisors summarize key product approvals from three classes and indications over this past year, including the December CRISPR and Vertex approval of Exa-cel, Biogen and Sage’s...
In our latest podcast, Back Bay Life Science Advisors focused on the chronic and rare disease development of kidney disease. Recently, there have been some changes in treatment, some recent commercial launches and...
With the DNB//Back Bay Partnership for Healthcare In the current markets, Healthcare continues to rally as the second-largest industry behind technology in the stock market, and in the US markets there’s been roughly...
A conversation on the rising trends in the cardiology space Cardiology has historically been a cornerstone of large pharmaceutical portfolios. The late 2000s and 2010s saw many pharmaceutical companies and investors...
In this episode, Dr. Peter Bak is joined by Trent Gordon and Dr. Mavra Nasir as they discuss their Bioprocess Online article published earlier this year, “The Transactional Landscape of ADCs: A Payday for Payloads.”...
Episode #18
The world of health tech has changed dramatically since decades ago when physicians had to endure 11 keystrokes to prescribe a single aspirin. These days, AI-based radiology and AI-based pathology are transforming...
For biopharma and medtech companies developing new treatments, capital for advancement and growth is invariably dependent on strategic preparation, differentiation, and persistence. Good preparation can mean funding or...
Recent guests on Back Bay Life Science Report. Study who booked and why before you pitch.
Managing Partner & COO, SV Health Investors
DNB Bank
Back Bay Life Science Advisors
Nasdaq
PitchCentric classifies Back Bay Life Science Report under these industries. Guests from them are the closest fit, and each links to the best podcasts in that industry.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
Bench to Boardroom
Biotech Talk
Life Sciences Today
Leap Together Podcast
MedTech Global Insights
Thoughts on Healthcare Markets & Technology Podcast
Is this podcast yours and you'd like to remove or correct details? Request removal or email privacy@pitchcentric.com.
Questions about the free trial? See the pricing FAQ